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ABSTRACT
Introduction: There is a need to better understand the
epidemiology of medication errors and error-related
adverse events in community care contexts.
Methods and analysis: We will systematically search
the following databases: Cumulative Index to Nursing
and Allied Health Literature (CINAHL), EMBASE,
Eastern Mediterranean Regional Office of the WHO
(EMRO), MEDLINE, PsycINFO and Web of Science. In
addition, we will search Google Scholar and contact an
international panel of experts to search for unpublished
and in progress work. The searches will cover the time
period January 1990–December 2015 and will yield
data on the incidence or prevalence of and risk factors
for medication errors and error-related adverse drug
events in adults living in community settings (ie,
primary care, ambulatory and home). Study quality will
be assessed using the Critical Appraisal Skills Program
quality assessment tool for cohort and case–control
studies, and cross-sectional studies will be assessed
using the Joanna Briggs Institute Critical Appraisal
Checklist for Descriptive Studies. Meta-analyses will be
undertaken using random-effects modelling using
STATA (V.14) statistical software.
Ethics and dissemination: This protocol will be
registered with PROSPERO, an international
prospective register of systematic reviews, and the
systematic review will be reported in the peer-reviewed
literature using Preferred Reporting Items for
Systematic Reviews and Meta-Analyses.
INTRODUCTION
Patient safety is a public concern in health-
care systems across the world.1 The National
Coordinating Council for Medication Error
Reporting and Prevention deﬁnes a medica-
tion error as ‘any preventable event that may
cause or lead to inappropriate medication
use or patient harm, while the medication is
in the control of the healthcare professional,
patient or consumer’.2 Medication errors are
therefore any mistakes at any stage of
medication management. Adverse drug event
(ADE), on the other hand, is ‘an injury result-
ing from medical intervention related to a
drug’, regardless of whether an error has
occurred.3 While almost all medication errors
can be prevented, ADEs can be categorised as
preventable and non-preventable.1 Box 1 pro-
vides deﬁnitions of the key terms employed in
this systematic review protocol.
Medication errors and error-related ADEs
are common and are responsible for con-
siderable patient harm.1 More speciﬁcally,
ADEs can lead to morbidity, hospitalisation,
increased healthcare costs and, in some cases,
death.4 It has been estimated that 5–6% of all
hospitalisations are drug-related.5 6 With esti-
mates suggesting that ADEs causing hospital
admission occur in around 10% of inpatients;
approximately half of these ADEs are believed
to be preventable.7
The cost of drug-related morbidity and
mortality was estimated to be $177.4 billion
annually in 2001 in the USA alone.8
Medication errors and ADEs are a major
problem in all care settings, including home,
ambulatory and community settings.1
Children and adults who suffer from multiple
long-term conditions with associated complex
drug regimens are particularly at risk.9–11
Systematic reviews focusing on the safety of
primary care contexts only have identiﬁed
studies with vastly different prevalence esti-
mates of the rates of medication errors, these
reﬂect differences in deﬁnitions, sampling
strategy and populations studied; none of
these have investigated the risk factors for
medication errors.12 13
Since the release of To Err is Human:
Building a Safer Health System by the Institute
of Medicine,14 which focused on acute care
settings, most patient safety research has
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been carried out on hospitalised patients.15 16 Given that
patients are increasingly managed in primary, ambula-
tory and home settings, there is a need to also focus
attention on community care contexts.
Prior to undertaking further primary work in this
area, it is important to take stock of the current evidence
base, reﬂect on the quality of the evidence, distil key
ﬁndings that have the potential to provide both esti-
mates on the frequency of medication errors and error-
related ADEs, and understand the factors underpinning
this important source of preventable harm. We will
therefore undertake a systematic review investigating the
incidence and prevalence of and risk factors for medica-
tion errors and error-related ADEs in community (ie,
primary care, ambulatory and home) settings.
Research question
What are the incidence and prevalence of and risk
factors for medication errors and error-related ADEs in
primary care, ambulatory care and home settings?
METHODS
Design
We will undertake a systematic review and, if possible, a
meta-analysis.
Inclusion criteria
Eligibility criteria
Type of studies
Population-based cross-sectional and cohort studies will
be eligible to estimate the incidence and prevalence of
medication errors and ADEs; these study designs and
case–control studies will be eligible to study risk factors
for the development of error-related ADEs.
Population
The population of interest will be adults (≥18 years)
who are dwelling in the community and living in their
own homes without home healthcare or nursing at
home. These patients may be self-managing, receiving
care in primary care and ambulatory settings or any
combination of the above.
Exposures
The exposure of interest is prescribed and/or
over-the-counter medications.
Outcomes
The outcomes of interest are the incidence and preva-
lence of medication errors and ADEs, and risk factors
for the development of medication errors and error-
related ADEs. These errors may have occurred anywhere
in the medicines’ management process.1 We will work
with the deﬁnitions of medication errors and error-
related ADEs employed in individual studies.
Exclusion criteria
1. Studies on illegal substance abuse, herbal products,
home healthcare (ie, continuous medical and/or
nursing care provided to patients in their own
homes), nursing home, hospitalised in-patients or
those managed in emergency department settings.
2. Paediatrics (<18 years).
3. Randomised controlled trials since these cannot be
used to reliably assess the incidence and/or preva-
lence of the outcomes of interest.
4. Existing reviews since the focus is on the primary
literature.
5. Studies focusing on speciﬁc medication errors or sub-
groups of populations.
6. Incompletely reported studies, for example, in the
form of abstracts.
Search strategy
We will search the following biomedical databases for
published research studies: Cumulative Index to Nursing
and Allied Health Literature (CINAHL), EMBASE,
Eastern Mediterranean Regional Ofﬁce of the WHO
(EMRO), MEDLINE, PsycINFO and Web of Science.
These databases will be searched from January 1990 to
December 2015; the start date has been chosen to
reﬂect the time when patient safety came into the con-
sciousness of policymakers, professionals and the
public.17 In addition, we will search Google Scholar and
contact an international panel of experts to search for
unpublished and in progress work. The corresponding
author of the eligible articles may be contacted if add-
itional information is needed. The reference list of pre-
vious studies will be scrutinised for additional possible
Box 1 Key definitions
▸ Adverse drug event (ADE): Bates et al3 define ADE as ‘an
injury resulting from medical intervention related to a drug’.
Some ADEs are caused by underlying medication errors.
▸ Medication error: The National Coordinating Council for
Medication Error Reporting and Prevention defines a medica-
tion error as: ‘any preventable event that may cause or lead to
inappropriate medication use or patient harm, while the medi-
cation is in the control of the healthcare professional, patient,
or consumer. Such events may be related to professional prac-
tice, healthcare products, procedures and systems, including
prescribing; order communication; product labelling, pack-
aging, and nomenclature; compounding; dispensing; distribu-
tion; administration; education; monitoring; and use’.2
Medication errors can result from any step of the
medication-use process: selection and procurement, storage,
ordering and transcribing, preparing and dispensing, adminis-
tration or monitoring.1
▸ Non-prescription drugs: Medicines that can be sold legally
without a drug prescription.
▸ Over-the-counter (OTC) drug: The Food and Drug
Administration defines OTC drugs as ‘drugs that have been
found to be safe and appropriate for use without the supervi-
sion of a healthcare professional such as a physician, and they
can be purchased by consumers without a prescription’.24
▸ Prescription drug: Drugs that cannot be sold legally without a
prescription.
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eligible studies. No restriction on the language of publi-
cation will be employed.
Detailed search strategies are presented in online sup-
plementary appendix 1.
Study selection
GA will search the databases. GA and a second reviewer
will then independently screen the titles and abstracts
for eligible studies according to the above detailed selec-
tion criteria. Full-text articles will be retrieved from
selected studies and will be reviewed according to the
selection criteria. Disagreements will be resolved by dis-
cussion between the reviewers or arbitration by a third
reviewer if a decision cannot be reached. Each copy of
the selected studies will be retrieved and the reason for
excluding other studies will be clearly noted.
Quality assessment
The risk of bias assessments will be independently
carried out on each study by two reviewers using the
Critical Appraisal Skills Program quality assessment tool
for cohort and case–control studies,18 and cross-sectional
studies will be assessed using the Joanna Briggs Institute
Critical Appraisal Checklist for Descriptive Studies.19
Any disagreements will be resolved by consensus or arbi-
tration by a third reviewer if a decision cannot be
reached. Each study will be graded as being at high,
medium or low risk of bias.
Data extraction
Data will be extracted by two reviewers and recorded
onto a customised data extraction sheet. Discrepancies
will be resolved by discussion. The following information
will be extracted:
1. Author, year;
2. Study design, study type (retrospective, prospective);
3. Population of interest;
4. Exposure of interest;
5. Outcomes of interest;
6. Main ﬁndings;
7. Conclusions;
8. Additional notes.
Data analysis
Data will be summarised in detailed data tables, which
will include information on the incidence, prevalence,
and relative risk and ORs, together with 95% CIs, for
each study (where available). STATA (V.14) statistical
software will be used to pool study data if this is consid-
ered both clinically and statistically appropriate.
Meta-analyses will be undertaken using random-effects
modelling.20
Sensitivity analyses will be undertaken by excluding
studies judged to be at the highest risk of bias.
Subgroup analyses will be undertaken comparing:
adults (18–64 years) versus elderly (≥65 years) patients;
and those who have recently been an inpatient or had a
hospital visit (<30 days) versus those who have not had a
recent hospital attendance (≥30 days).
If possible, funnel plots will be used to assess the pres-
ence of publication bias.21
Registration and reporting
This systematic review will be registered with
PROSPERO, an international prospective register of
systematic reviews, and will be reported using Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses22 and Meta-analysis Of Observational Studies in
Epidemiology guidelines.23
DISCUSSION
This systematic review will provide a comprehensive assess-
ment of the epidemiology of medication errors and error-
related ADEs in community settings. We anticipate report-
ing the ﬁndings from this study in the autumn of 2016.
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